×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
💹
Economics
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Economics
Status
Showcase
▼
Showcase
Demo
Vision
|
Showcase
←
Home
/
Wiki
/
Clinical: CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
clinical
3,284 words
KG: CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
topic:alzheimers
topic:stress
topic:glucocorticoid
topic:mci
Contents
CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
Knowledge Graph
Related Hypotheses (26)
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
APOE Isoform Conversion Therapy
Score: 0.72
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
Score: 0.71
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.67
RNA Granule Nucleation Site Modulation
Score: 0.66
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Vocal Cord Neuroplasticity Stimulation
Score: 0.72
Vagal Afferent Microbial Signal Modulation
Score: 0.66
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.76
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
Multi-Modal Stress Response Harmonization
Score: 0.76
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.72
Stress Granule Phase Separation Modulators
Score: 0.72
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.68
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.67
Nucleolar Stress Response Normalization
Score: 0.65
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.64
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.63
Show 21 more
Related Analyses (11)
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Show 6 more
Related Experiments (4)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
See Also (15)
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 7 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Trace Amine-Associated Receptor (TAAR) Modulator Therap
therapeutic · Pages share 7 hypotheses
SYK Kinase Inhibitor Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
STING Inhibitor Therapy in Neurodegeneration
therapeutic · Pages share 7 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapy for Ne
therapeutic · Pages share 7 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapies for
therapeutic · Pages share 7 hypotheses
Somatostatin Receptor Modulator Therapy in Neurodegener
therapeutic · Pages share 7 hypotheses
S100 Protein (S100A8/A9/A12) Modulator Therapy for Neur
therapeutic · Pages share 7 hypotheses
RNA Targeting Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Progranulin Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
nt-3-therapy-neurodegeneration
therapeutic · Pages share 7 hypotheses
Neurotensin Receptor Modulator Therapy for Neurodegener
therapeutic · Pages share 7 hypotheses
Nanoparticle Drug Delivery for Neurodegeneration
therapeutic · Pages share 7 hypotheses
N-Acetylcysteine Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Show 10 more
Knowledge Graph (2 edges)
CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
references
APOE
CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
references
BDNF
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)